Can healthtech unicorns exit the pipeline?
Only two new healthtech unicorns were minted in 2023, compared with 2021 and 2022, which had 52 combined.
Not only has the rapid shift in market conditions slowed funding for healthtech specialists, but also many of the unicorns born during the COVID-19 bubble have been unable to successfully go public or seek other exit opportunities, creating a backlog of late-stage startups.
Our latest analyst note breaks down deal trends, M&A opportunities, top IPO candidates, and more among healthtech unicorns.
Table of contents
| Key takeaways | 1 |
| Introduction | 2 |
| Stalled funding, outdated valuations | 3 |
| Shifting market expectations | 4 |
| Healthtech unicorn M&A outlook | 5 |
| 2024 IPO watch | 6 |
| Evaluating healthtech unicorn prospects | 6 |
| Appendix | 13 |